NCT04609241View on ClinicalTrials.gov

CD79b CAR-T Cell Therapy for Patients With Relapsed and/or Refractory Acute Lymphoblastic Leukemia and B-cell Non-Hodgkin's Lymphoma

EARLY_PHASE1Not yet recruitingINTERVENTIONAL
Enrollment

72

Participants

Timeline

Start Date

November 15, 2020

Primary Completion Date

November 15, 2023

Study Completion Date

November 15, 2026

Conditions
Relapsed and/or Refractory Acute Lymphoblastic LeukemiaRelapsed and/or Refractory B-cell Non-Hodgkin's Lymphoma
Interventions
DRUG

CD79b CAR-T Cells

Each subject receive CD79b CAR-Tcells by intravenous infusion

Trial Locations (1)

Unknown

The First Affiliated Hospital, College of Medicine, Zhejiang University, Hangzhou

All Listed Sponsors
collaborator

Yake Biotechnology Ltd.

INDUSTRY

lead

Zhejiang University

OTHER

NCT04609241 - CD79b CAR-T Cell Therapy for Patients With Relapsed and/or Refractory Acute Lymphoblastic Leukemia and B-cell Non-Hodgkin's Lymphoma | Biotech Hunter | Biotech Hunter